Advances in Sharing Multi-sourced Health Data on Decision Support Science 2016-2017

Translating an evidence-based clinical pathway into shareable CDS: developing a systematic process using publicly available tools

OBJECTIVE

To develop a process for translating semi-structured clinical decision support (CDS) into shareable, computer-readable CDS.

MATERIALS AND METHODS

We developed a systematic and transparent process using publicly available tools (eGLIA, GEM Cutter, VSAC, and the CDS Authoring Tool) to translate an evidence-based clinical pathway (CP) into a Clinical Quality Language (CQL)-encoded CDS artifact.

RESULTS

We produced a 4-phase process for translating a CP into a CQL-based CDS artifact. CP content was extracted using GEM into discrete clinical concepts, encoded using standard terminologies into value sets on VSAC, evaluated against workflows using a wireframe, and finally structured as a computer readable CDS artifact using CQL. This process included a quality control step and intermediate products to support transparency and reuse by other CDS developers.

DISCUSSION

Translating a CP into a shareable, computer-readable CDS artifact was accomplished through a systematic process. Our process identified areas of ambiguity and gaps in the CP, which generated improvements in the CP. Collaboration with clinical subject experts and the CP development team was essential for translation. Publicly available tools were sufficient to support most translation steps, but expression of certain complex concepts required manual encoding.

CONCLUSION

Standardized development of CDS from a CP is feasible using a systematic 4-phase process. CPs represent a potential reservoir for developers of evidence-based CDS. Aspects of CP development simplified portions of the CDS translation process. Publicly available tools can facilitate CDS development; however, enhanced tool features are needed to model complex CDS statements.

Clinical decision support systems for chronic diseases: A Systematic literature review

A Clinical Decision Support System (CDSS) aims to assist physicians, nurses and other professionals in decision-making related to the patient's clinical condition. CDSSs deal with pertinent and critical data, and special care should be taken in their design to ensure the development of usable, secure and reliable tools.

OBJECTIVE

This paper aims to investigate existing literature dealing with the development process of CDSSs for monitoring chronic diseases, analysing their functionalities and characteristics, and the software engineering representation in their design.

METHODS

A systematic literature review (SLR) is conducted to analyse the literature on CDSSs for monitoring chronic diseases and the application of software engineering techniques in their design.

RESULTS

Fourteen included studies revealed that the most addressed disease was diabetes (42.8%) and the most commonly proposed approach was diagnostic (85.7%). Regarding data sources, the studies show a predominance on the use of databases (85.7%), with other data sources such as sensors (42.8%) and self-report (28.6%) also being considered. Analysing the representation for engineering techniques, we found Behaviour diagrams (42.8%) to be the most frequent, closely followed by Structural diagrams (35.7%) and others (78.6%) being largely mentioned. Some studies also approached the requirement specification (21.4%). The most common target evaluation was the performance of the system (64.2%) and the most common metric was accuracy (57.1%).

CONCLUSION

We conclude that software engineering, in its completeness, has scarce representation in studies focused on the development of CDSSs for chronic diseases.

CURATE.AI: Optimizing Personalized Medicine with Artificial Intelligence

The clinical team attending to a patient upon a diagnosis is faced with two main questions: what treatment, and at what dose? Clinical trials' results provide the basis for guidance and support for official protocols that clinicians use to base their decisions upon. However, individuals rarely demonstrate the reported response from relevant clinical trials, often the average from a group representing a population or subpopulation. The decision complexity increases with combination treatments where drugs administered together can interact with each other, which is often the case. Additionally, the individual's response to the treatment varies over time with the changes in his or her condition, whether via the indication or physiology. In practice, the drug and the dose selection depend greatly on the medical protocol of the healthcare provider and the medical team's experience. As such, the results are inherently varied and often suboptimal. Big data approaches have emerged as an excellent decision-making support tool, but their application is limited by multiple challenges, the main one being the availability of sufficiently big datasets with good quality, representative information. An alternative approach-phenotypic personalized medicine (PPM)-finds an appropriate drug combination (quadratic phenotypic optimization platform [QPOP]) and an appropriate dosing strategy over time (CURATE.AI) based on small data collected exclusively from the treated individual. PPM-based approaches have demonstrated superior results over the current standard of care. The side effects are limited while the desired output is maximized, which directly translates into improving the length and quality of individuals' lives.

Technical, Biological, and Systems Barriers for Molecular Clinical Decision Support

Genome-enabled or molecular clinical decision support (CDS) systems provide unique advantages for the clinical use of genomic data; however, their implementation is complicated by technical, biological, and systemic barriers. This article reviews the substantial technical progress that has been made in the past decade and finds that the underlying biological limitations of genomics as well as systemic barriers to adoption of molecular CDS have been comparatively underestimated. A hybrid consultative CDS system, which integrates a genomics consultant into an active CDS system, may provide an interim path forward.